Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 8705-8712

  Liu, Qingquan ^a,b   Sun, Yongtao ^b   Rihn, Suzannah ^a   Nolting, Anne ^a   Tsoukas, Peter Nicholas ^a   Jost, Stephanie ^a   Cohen, Kristen ^a   Walker, Bruce ^a,c   Alter, Galit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; GALLARDIN; ILOMASTAT; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; DRUG ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET CELL; TISSUE REPAIR; VIRUS LOAD; BIOSYNTHESIS; CYTOTOXICITY TEST; FEMALE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED;

HARNESS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; RECEPTORS, IGG;

EID: 69249213610     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02666-08     Document Type: Article

References (45)

1. Aasa-Chapman, M. M., S. Holuigue, K. Aubin, M. Wong, N. A. Jones, D. Cornforth, P. Pellegrino, P. Newton, I. Williams, P. Borrow, and A. McKnight. 2005. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79:2823-2830.
2. Ahmad, A., R. Morisset, R. Thomas, and J. Menezes. 1994. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 7:428-437.
3. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:15-22. (Pubitemid 39626587)
4. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, J. D. Lifson, T. M. Allen, M. Carrington, and M. Altfeld. 2007. Differential natural killer cellmediated inhibition of HIV-1 replication based on distinct KIR/HLA sub-types. J. Exp. Med. 204:3027-3036.
5. Alter, G., N. Teigen, B. T. Davis, M. M. Addo, T. J. Suscovich, M. T. Waring, H. Streeck, M. N. Johnston, K. D. Staller, M. T. Zaman, X. G. Yu, M. Lichterfeld, N. Basgoz, E. S. Rosenberg, and M. Altfeld. 2005. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106:3366-3369. (Pubitemid 41609166)
6. Alter, G., C. M. Tsoukas, D. Rouleau, P. Cote, J. P. Routy, R. P. Sekaly, and N. F. Bernard. 2004. Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection. AIDS 18:1979-1989. (Pubitemid 39463351)
7. Azzoni, L., E. Papasavvas, J. Chehimi, J. R. Kostman, K. Mounzer, J. Ondercin, B. Perussia, and L. J. Montaner. 2002. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J. Immunol. 168:5764-5770. (Pubitemid 34556161)
8. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
9. De Maria, A., M. Fogli, P. Costa, G. Murdaca, F. Puppo, D. Mavilio, A. Moretta, and L. Moretta. 2003. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol. 33:2410-2418. (Pubitemid 37138973)
10. Eger, K. A., and D. Unutmaz. 2004. Perturbation of natural killer cell function and receptors during HIV infection. Trends Microbiol. 12:301-303. (Pubitemid 38829648)
11. Fogli, M., P. Costa, G. Murdaca, M. Setti, M. C. Mingari, L. Moretta, A. Moretta, and A. De Maria. 2004. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur. J. Immunol. 34:2313-2321.
12. Forthal, D. N., G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya. 2007. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923.
13. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75:6953-6961.
14. Forthal, D. N., G. Landucci, R. Haubrich, B. Keenan, B. D. Kuppermann, J. G. Tilles, and J. Kaplan. 1999. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180:1338-1341.
15. Forthal, D. N., G. Landucci, and B. Keenan. 2001. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retrovir. 17:553-561.
16. Galiani, M. D., E. Aguado, R. Tarazona, P. Romero, I. Molina, M. Santamaria, R. Solana, and J. Pena. 1999. Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals. Clin. Exp. Immunol. 115: 472-476.
17. Gandhi, R. T., and B. D. Walker. 2002. Immunologic control of HIV-1. Annu. Rev. Med. 53:149-172.
18. Giorgi, J. V., Z. Liu, L. E. Hultin, W. G. Cumberland, K. Hennessey, and R. Detels. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6:904-912.
19. Grzywacz, B., N. Kataria, and M. R. Verneris. 2007. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21:356-359. (Pubitemid 46158133)
20. Harrison, D., J. H. Phillips, and L. L. Lanier. 1991. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J. Immunol. 147:3459-3465.
21. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, P. A. Marx, and D. R. Burton. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
22. Hildreth, J. E., R. Hampton, and N. A. Halsey. 1999. Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Clin. Immunol. 90:203-212.
23. Hu, P. F., L. E. Hultin, P. Hultin, M. A. Hausner, K. Hirji, A. Jewett, B. Bonavida, R. Detels, and J. V. Giorgi. 1995. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:331-340.
24. Jennes, W., S. Verheyden, C. Demanet, C. A. Adje-Toure, B. Vuylsteke, J. N. Nkengasong, and L. Kestens. 2006. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 177:6588-6592. (Pubitemid 44715020)
25. Jewett, A., M. Cavalcanti, J. Giorgi, and B. Bonavida. 1997. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J. Immunol. 158:5492-5500. (Pubitemid 127681258)
26. Katz, J. D., R. Mitsuyasu, M. S. Gottlieb, L. T. Lebow, and B. Bonavida. 1987. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J. Immunol. 139:55-60.
27. Kottilil, S., K. Shin, M. Planta, M. McLaughlin, C. W. Hallahan, M. Ghany, T. W. Chun, M. C. Sneller, and A. S. Fauci. 2004. Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. J. Infect. Dis. 189:1193-1198.
28. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23:225-274.
29. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9:495-502.
30. Ljunggren, K., A. Karlson, E. M. Fenyo, and M. Jondal. 1989. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin. Exp. Immunol. 75:184-189.
31. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, M. Wilson, S. J. O'Brien, and M. Carrington. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-434.
32. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, J. J. Goedert, S. Buchbinder, G. D. Kirk, A. Telenti, M. Connors, S. J. O'Brien, B. D. Walker, P. Parham, S. G. Deeks, D. W. McVicar, and M. Carrington. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39:733-740.
33. Mastroianni, C. M., and G. M. Liuzzi. 2007. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol. Med. 13:449-459.
34. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100:15011-15016.
35. Mavilio, D., G. Lombardo, A. Kinter, M. Fogli, A. La Sala, S. Ortolano, A. Farschi, D. Follman, R. Gregg, C. Kovacs, E. Marcenaro, D. Pende, A. Moretta, and A. S. Fauci. 2006. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203:2339-2350.
36. Moretta, A., C. Bottino, M. C. Mingari, R. Biassoni, and L. Moretta. 2002. What is a natural killer cell? Nat. Immunol. 3:6-8. (Pubitemid 34065607)
37. Parker, S. J., T. A. Sadlon, and D. L. Gordon. 1995. Enhancement of NK cell-mediated antibody-dependent lysis of recombinant gp120-coated CD4 cells by complement. J. Infect. Dis. 171:186-189.
38. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-4149.
39. Scott-Algara, D., L. X. Truong, P. Versmisse, A. David, T. T. Luong, N. V. Nguyen, I. Theodorou, F. Barre-Sinoussi, and G. Pancino. 2003. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171:5663-5667. (Pubitemid 37467178)
40. Sirianni, M. C., F. Ensoli, C. Alario, V. Fiorelli, G. Sacco, S. Topino, F. Iebba, I. Mezzaroma, and F. Aiuti. 2001. Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection. Hum. Immunol. 62:1328-1334.
41. Trinchieri, G., and N. Valiante. 1993. Receptors for the Fc fragment of IgG on natural killer cells. Nat. Immun. 12:218-234.
42. Tu, G., W. Xu, H. Huang, and S. Li. 2008. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15:1388-1395.
43. Tyler, D. S., S. D. Stanley, C. A. Nastala, A. A. Austin, J. A. Bartlett, K. C. Stine, H. K. Lyerly, D. P. Bolognesi, and K. J. Weinhold. 1990. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J. Immunol. 144:3375-3384.
44. Webster, N. L., and S. M. Crowe. 2006. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J. Leukoc. Biol. 80:1052-1066.
45. Weeks, B. S. 1998. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (review). Int. J. Mol. Med. 1:361-366.